CLO20-039: Patient (pt)-Reported Outcomes (PRO) in Patients With HER2-Negative Locally Advanced/Metastatic Breast Cancer (LA/mBC) and a Germline BRCA1/2 Mutation (gBRCA1/2 mut) Receiving Talazoparib vs. Physician’s Choice of Chemotherapy (PCT): A Focus on EMBRACA Racial Subgroups